Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions

Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition

(2020) Nur Aininie Yusoh et al.   ACS Chemical Biology

FGFR3 signaling and function in triple negative breast cancer

(2020) Nicole J. Chew et al.   Cell Communication and Signaling

Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage

(2020) Meghna Mehta et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types

(2020) Guan Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

(2020) Florence Coussy et al.   Science Translational Medicine

Retraction: UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer

(2020) Rabia A. Gilani et al.   CLINICAL CANCER RESEARCH

Inhibiting fatty acid synthase in operable triple negative breast cancer.

(2020) Sagar D. Sardesai et al.   JOURNAL OF CLINICAL ONCOLOGY

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

(2020) Tian-Hao Weng et al.   Cancer Research and Treatment

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

(2020) Yi-Zhou Jiang et al.   CELL RESEARCH

SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR

(2020) Lina Zhao et al.   Advanced Science

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer

(2020) Jiande Wu et al.   Cancers

Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma

(2020) Silvia González-Martínez et al.   Cancers

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells

(2019) Fei Jiang et al.   CELL BIOLOGY AND TOXICOLOGY

Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression

(2019) Chun-Yu Liu et al.   EBioMedicine

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells

(2019) Chun-Yu Liu et al.   Cancers

Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple negative breast cancer

(2019) Brock A Humphries et al.   MOLECULAR CANCER RESEARCH

Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer

(2019) Murugan Kalimutho et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer

(2019) Jangsoon Lee et al.   BREAST CANCER RESEARCH AND TREATMENT

New Drug Approvals in 2018 – Another Record Year!

(2019) Alex M Ebied et al.   AMERICAN JOURNAL OF MEDICINE

C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition

(2019) Tae-Min Cho et al.   CANCER LETTERS

Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer

(2019) Shengling Fu et al.   CANCER LETTERS

Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer

(2019) Qiang He et al.   CANCER LETTERS

GSK2801, A BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer

(2019) Samantha M. Bevill et al.   MOLECULAR CANCER RESEARCH

Acquired short QT syndrome in a cancer patient treated with Toad

(2019) Yan Huang et al.   PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY

Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2

(2019) Zhenyuan Gao et al.   PATHOLOGY RESEARCH AND PRACTICE

A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair

(2019) Zhiwang Song et al.   Cell Death & Disease

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

(2019) Constantia Pantelidou et al.   Cancer Discovery

Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers

(2019) Mathilde Vinet et al.   Cancer Medicine

A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy

(2019) Zhuan Zhou et al.   EBioMedicine

TRPC3 Regulates the Proliferation and Apoptosis Resistance of Triple Negative Breast Cancer Cells through the TRPC3/RASA4/MAPK Pathway

(2019) Wang et al.   Cancers

Co-Targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy

(2019) Andrew Sulaiman et al.   MOLECULAR CANCER THERAPEUTICS

Phenothiazine antipsychotics exhibit dual properties in pseudo-allergic reactions: Activating MRGPRX2 and inhibiting the H1 receptor

(2019) Yajing Hou et al.   MOLECULAR IMMUNOLOGY

Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer

(2019) Yingjia Ni et al.   Nature Communications

Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis

(2019) Hui Cai et al.   Advanced Science

A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer

(2019) Richard D. A. Wilkinson et al.   Journal of Oncology

A Sesquiterpenoid from Farfarae Flos Induces Apoptosis of MDA-MB-231 Human Breast Cancer Cells through Inhibition of JAK–STAT3 Signaling

(2019) Hyeri Jang et al.   Biomolecules

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

(2019) Jichao He et al.   BREAST CANCER RESEARCH AND TREATMENT

PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges

(2019) Mohammad A. Khan et al.   DRUG DISCOVERY TODAY

JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer

(2019) Ying Tian et al.   ACS Applied Materials & Interfaces

Targeted Therapies for Triple-Negative Breast Cancer

(2019) Tomas G. Lyons   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model

(2019) Qiulei Zhang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression

(2019) Sourav Banerjee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

(2019) Lei Nie et al.   Nature Communications

Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer

(2019) In Hae Park et al.   Scientific Reports

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer

(2019) Vera E. van der Noord et al.   Scientific Reports

Targeting autophagy-related protein kinases for potential therapeutic purpose

(2019) Honggang Xiang et al.   Acta Pharmaceutica Sinica B

1,3-Dicaffeoylquinic acid targeting 14-3-3 tau suppresses human breast cancer cell proliferation and metastasis through IL6/JAK2/PI3K pathway

(2019) Yuhang Zhou et al.   BIOCHEMICAL PHARMACOLOGY

Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling

(2019) Deepak KGK et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

(2019) Peter Schmid et al.   JOURNAL OF CLINICAL ONCOLOGY

Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells

(2019) Sameer S. Chopra et al.   Cell Systems

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

(2018) Y Bareche et al.   ANNALS OF ONCOLOGY

Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling

(2018) Wei Chen et al.   BIOMEDICINE & PHARMACOTHERAPY

Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/ PI3K/Akt pathway

(2018) Jianjun Han et al.   Bosnian Journal of Basic Medical Sciences

Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer

(2018) Nashwa Kabil et al.   BREAST CANCER RESEARCH AND TREATMENT

Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF-1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment

(2018) Haiquan Lu et al.   CANCER RESEARCH

Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies

(2018) Alice Lee et al.   CANCER TREATMENT REVIEWS

Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer

(2018) Yongzhi Guo et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition

(2018) Eunhye Oh et al.   INTERNATIONAL JOURNAL OF CANCER

Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB�231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2

(2018) Dong Young Kang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

(2018) Tiffany A. Traina et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

(2018) Daniele Cretella et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

131 -Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal-epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo

(2018) Soumaya Souid et al.   MOLECULAR CARCINOGENESIS

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer

(2018) Amritha Nair et al.   NATURE MEDICINE

Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide

(2018) Lu Lu et al.   ONCOGENE

AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature

(2018) Melissa Davis et al.   PLoS One

Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth

(2018) Chunyan Ren et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression

(2018) Linda Xiaoyan Li et al.   Cell Death & Disease

Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis

(2018) Chuan Cao et al.   CELL PROLIFERATION

BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy

(2018) C. Mio et al.   INTERNATIONAL JOURNAL OF CANCER

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial

(2018) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+).

(2018) Jennifer Keating Litton et al.   JOURNAL OF CLINICAL ONCOLOGY

An open label, pilot study of veliparib (ABT-888) and lapatinib in patients with metastatic, triple negative (ER, PR, and HER-2 negative) breast cancer.

(2018) Erica Michelle Stringer-Reasor et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudopterosin Inhibits Proliferation and 3D Invasion in Triple-Negative Breast Cancer by Agonizing Glucocorticoid Receptor Alpha

(2018) Julia Sperlich et al.   MOLECULES

Comparative Effectiveness of an mTOR‐Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple‐Negative Breast Cancer

(2018) Reva K. Basho et al.   ONCOLOGIST

Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells

(2018) Sangmin Kim et al.   PHYTOMEDICINE

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines

(2018) Aleksandra Simiczyjew et al.   Cancers

Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells

(2018) Jun Tian et al.   BRITISH JOURNAL OF CANCER

Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer

(2018) Wenlong Li et al.   ONCOLOGY REPORTS

The clinical promise of immunotherapy in triple-negative breast cancer

(2018) Praveen Vikas et al.   Cancer Management and Research

Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer

(2017) Dahong Yao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells

(2017) Yin Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer

(2017) Shiyi Yu et al.   International Journal of Biological Sciences

Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer

(2017) Liang Ouyang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer

(2017) Takashi Ishikawa et al.   JOURNAL OF SURGICAL RESEARCH

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2017) Sung-Bae Kim et al.   LANCET ONCOLOGY

PIM1: a promising target in patients with triple-negative breast cancer

(2017) Wen Zhao et al.   MEDICAL ONCOLOGY

Integrating multiple omics data for the discovery of potential Beclin-1 interactions in breast cancer

(2017) Yi Chen et al.   Molecular BioSystems

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms

(2017) Marie D. Ralff et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells

(2017) Chun-Yu Liu et al.   Molecular Oncology

Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer

(2017) Bo Yang et al.   NATURAL PRODUCT RESEARCH

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer

(2017) Amanda E D Van Swearingen et al.   NEURO-ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer

(2017) Debashree Basudhar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

(2017) Delphine Merino et al.   Science Translational Medicine

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

(2017) Lan Zhang et al.   Chemical Science

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

(2017) Jon S. Zawistowski et al.   Cancer Discovery

Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer

(2017) Hui Liu et al.   Cancer Discovery

Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells

(2017) Yujuan Chen et al.   Oncotarget

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer

(2017) Reva K. Basho et al.   JAMA Oncology

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)

(2017) Xiao-Long Qian et al.   PLoS One

Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer

(2016) Yu-qian Zhao et al.   ACTA PHARMACOLOGICA SINICA

An overview of the effective combination therapies for the treatment of breast cancer

(2016) Cristina Núñez et al.   BIOMATERIALS

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

(2016) Daniel Rayson et al.   BREAST CANCER RESEARCH AND TREATMENT

PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion

(2016) Hamid H. Gari et al.   CANCER LETTERS

Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis

(2016) Nandini Verma et al.   CANCER RESEARCH

BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling

(2016) Guillaume Andrieu et al.   CANCER RESEARCH

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers

(2016) Rana Hatem et al.   INTERNATIONAL JOURNAL OF CANCER

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer

(2016) Chun-Hui Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer

(2016) Nathan Simon et al.   JNCI-Journal of the National Cancer Institute

Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy

(2016) Bowen Ke et al.   MEDICINAL RESEARCH REVIEWS

Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells

(2016) Zhiqiang Yao et al.   Molecular BioSystems

Systematic network-based discovery of a Fam20C inhibitor (FL-1607) with apoptosis modulation in triple-negative breast cancer

(2016) Ziyi Qin et al.   Molecular BioSystems

Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model

(2016) Hui-Wen Chiu et al.   Molecular Cancer

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells

(2016) Prson Gautam et al.   Molecular Cancer

Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer

(2016) K. A. Ludwik et al.   MOLECULAR CANCER THERAPEUTICS

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling

(2016) Zuzana Koledova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells

(2016) Yacine Merrouche et al.   Oncotarget

Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status

(2016) He-Sheng Jiang et al.   Oncotarget

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers

(2016) Erik S. Linklater et al.   Oncotarget

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

(2016) Abderrahim El Guerrab et al.   Oncotarget

MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase

(2016) Recep Bayraktar et al.   Oncotarget

Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer

(2016) Leilei Fu et al.   Scientific Reports

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer

(2016) Nathan Simon et al.   JNCI-Journal of the National Cancer Institute

Anticancer Effects of the Hsp90 Inhibitor 17-Demethoxy-Reblastatin in Human Breast Cancer MDA-MB-231 Cells

(2016) Qing Zhao et al.   JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

(2015) S. Moulder et al.   ANNALS OF ONCOLOGY

Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model

(2015) A. R. R. Maia et al.   ANNALS OF ONCOLOGY

Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line

(2015) Ayunadirah Ayub et al.   BIOMEDICINE & PHARMACOTHERAPY

Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells

(2015) Jaemoo Chun et al.   CANCER LETTERS

Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy

(2015) Qixing Tan et al.   CANCER SCIENCE

mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer

(2015) W. Mo et al.   CLINICAL CANCER RESEARCH

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

1977 Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC)

(2015) A. Bardia et al.   EUROPEAN JOURNAL OF CANCER

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

(2015) Fergus J. Couch et al.   JOURNAL OF CLINICAL ONCOLOGY

Design, Synthesis, and Structure–Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer

(2015) Chun-Hui Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer

(2015) Lan Zhang et al.   Molecular BioSystems

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer

(2015) M.-W. Zheng et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases

(2015) K. Kai et al.   MOLECULAR CANCER THERAPEUTICS

Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells

(2015) A. Schech et al.   MOLECULAR CANCER THERAPEUTICS

Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer

(2015) Mohamad Elbaz et al.   Molecular Oncology

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer

(2015) Bo Liu et al.   Oncotarget

Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer

(2015) Jangsoon Lee et al.   Journal of Cancer

Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells

(2015) Hyunsook An et al.   PLoS One

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)

(2015) Yoshie Hasegawa et al.   PLoS One

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†

(2014) A. M. Gonzalez-Angulo et al.   ANNALS OF ONCOLOGY

The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis

(2014) Un-Ho Jin et al.   BMC CANCER

Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells

(2014) Hongcheng Zhu et al.   CELL STRESS & CHAPERONES

Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K

(2014) J. C. Liu et al.   EMBO Molecular Medicine

Extrapyramidal symptoms following administration of oral perphenazine 4 or 8 mg

(2014) John P. Henao et al.   EUROPEAN JOURNAL OF ANAESTHESIOLOGY

Cross-talk between Endoplasmic Reticulum (ER) Stress and the MEK/ERK Pathway Potentiates Apoptosis in Human Triple Negative Breast Carcinoma Cells

(2014) Swatilekha Ghosh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth

(2014) Thanh U. Barbie et al.   JOURNAL OF CLINICAL INVESTIGATION

VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2

(2014) D Zhao et al.   ONCOGENE

The Potent Cdc7-Dbf4 (DDK) Kinase Inhibitor XL413 Has Limited Activity in Many Cancer Cell Lines and Discovery of Potential New DDK Inhibitor Scaffolds

(2014) Nanda Kumar Sasi et al.   PLoS One

Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation

(2014) Lara Lacerda et al.   Stem Cells Translational Medicine

Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women

(2013) Edoardo Botteri et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

(2013) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Reactivation of Estrogen Receptor α by Vorinostat Sensitizes Mesenchymal-Like Triple-Negative Breast Cancer to Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor

(2013) Karri Stark et al.   PLoS One

Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR

(2013) D. A. Ferraro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients

(2013) Minghui Zhang et al.   Targeted Oncology

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

(2012) D. W. Craig et al.   MOLECULAR CANCER THERAPEUTICS

High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients

(2012) C. Bartholomeusz et al.   ONCOLOGIST

Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer

(2011) Soley Bayraktar et al.   CANCER

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

(2011) Lauren L.C. Marotta et al.   JOURNAL OF CLINICAL INVESTIGATION

Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer

(2011) Amal Melhem-Bertrandt et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray

(2011) Jiehua He et al.   MEDICAL ONCOLOGY

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

(2010) Jean-Yves Pierga et al.   BREAST CANCER RESEARCH AND TREATMENT

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET